Biocytogen Sets 21 May 2026 AGM: No 2025 Dividend, Seeks RMB1.00 B Credit Line and Capital Increase

Bulletin Express04-23

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has released its AGM circular, outlining key resolutions to be tabled on 21 May 2026.

• 2025 Operating Highlights  – Revenue: RMB1.38 billion, up 40.63% year-on-year.  – Net profit attributable to shareholders: RMB173.20 million, up 416.37%.  – Net profit after extraordinary items: RMB116.08 million, up 405.39%.

• Profit Distribution  – The Board proposes no final dividend for 2025, retaining earnings to support business development.

• Auditor  – Re-appointment of KPMG as external auditor for 2026 with expected fee of approximately RMB3.80 million.

• Directors’ Remuneration  – 2025 cash remuneration, benefits and bonuses totalled RMB15.78 million; share-based payments were RMB9.18 million.  – 2026 remuneration scheme to follow existing performance-linked structure and is submitted for shareholder approval.

• Related-Party Transactions  – 2025 related-party sales and services included, among others, RMB349.67 million to Biocytogen Jiangsu and RMB93.24 million to Biocytogen Boston.  – Purchase of goods and services from group entities amounted to RMB62.60 million.  – Outstanding guarantees at year-end: RMB150.55 million.  – Daily related-party transactions for 2026 are estimated not to exceed RMB80 million (excluding potential royalty income).

• Financing & Guarantees  – The Company intends to secure consolidated bank credit facilities of up to RMB1.00 billion for working capital, project loans and trade finance.  – Biocytogen will provide joint-and-several guarantees for borrowings of wholly-owned subsidiaries within this limit.

• Registered Capital Adjustment  – Reflecting the December 2025 IPO of 47.50 million A shares, registered capital will rise from RMB399.40 million to RMB446.90 million.  – Corresponding amendments to the Articles of Association are proposed.

• AGM Logistics  – Date & time: 21 May 2026, 2:00 p.m. (physical meeting in Beijing with online participation).  – H-share register closes 18–21 May 2026; shareholders on record as of 21 May may vote.

All resolutions—including the work report, auditor re-appointment, remuneration, related-party transactions, credit facilities, and capital increase—will be decided by poll at the AGM.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment